An MCP joint injection delivers medication directly into one or more metacarpophalangeal joints, the large knuckles where your fingers meet the palm of your hand. Corticosteroids are the most common substance injected, and the goal is straightforward: reduce inflammation and pain that oral medications, splinting, or therapy have failed to control. The procedure takes just a few minutes in a clinic setting, but the decisions surrounding it, from what drug and dose to use to whether imaging guidance is worthwhile, are more nuanced than the injection itself.
When an MCP Joint Injection Makes Sense
The MCP joints take a beating from several forms of arthritis. Rheumatoid arthritis (RA) is the most common reason these knuckles get injected, since RA has a well-known preference for the small joints of the hands. Osteoarthritis, psoriatic arthritis, and crystal-deposit diseases like gout can also cause painful swelling at the MCP level. Treatment for index finger MCP arthritis, for example, typically starts with oral anti-inflammatory drugs, splinting, and occupational therapy before injections come into the picture.1Orthopedic Clinics of North America. Index Finger Metacarpophalangeal Joint Arthritis Injections enter the conversation when a specific joint remains swollen and painful despite those first-line measures, or when a patient needs targeted relief in one or two joints rather than a systemic medication change.
In RA, corticosteroid injections into the MCP joints also serve a bridging role. When a patient starts or switches a disease-modifying drug, it can take weeks or months for the systemic medication to kick in. An injection into a particularly inflamed knuckle can buy comfort during that gap. For osteoarthritis at this level, injections are more of a palliative measure: they do not slow the disease, but they can restore enough hand function that someone can grip a jar or button a shirt again.
Corticosteroid Choices and Dosing
Most clinicians use either methylprednisolone or triamcinolone acetonide for MCP joint injections. A narrative review of small and intermediate joint injections found that the typical dose range for small joints like the MCP is about 10 to 20 milligrams of either drug.2PM&R. Comparison of Varying Corticosteroid Type, Dose, and Volume for the Treatment of Pain in Small- and Intermediate-Size Joint Injections: A Narrative Review There is surprisingly little head-to-head research comparing different steroids in these joints. One randomized trial found triamcinolone hexacetonide, a less soluble formulation that stays in the joint longer, outperformed methylprednisolone in the interphalangeal finger joints, but no comparable study has been done specifically at the MCP level.3PM&R. Comparison of Varying Corticosteroid Type, Dose, and Volume for the Treatment of Pain in Small- and Intermediate-Size Joint Injections: A Narrative Review The same review noted that no studies have evaluated whether the volume of injectate affects outcomes, meaning clinicians are largely working from tradition and clinical judgment rather than hard data.
In practice, many providers mix a small volume of local anesthetic (usually lidocaine) with the corticosteroid. The anesthetic gives immediate but short-lived pain relief, which doubles as a diagnostic confirmation: if the pain vanishes for an hour or two, the problem was indeed coming from inside that joint. The steroid itself takes a day or two to start working and typically peaks around a week after the injection.
Does Ultrasound Guidance Matter for Small Joints?
Injecting an MCP joint without imaging is standard practice in many rheumatology and primary care offices. The clinician identifies the joint by feel, positions the needle at the dorsal surface (the back of the knuckle), and advances it into the joint space. For experienced hands, this works well enough in many cases. But research consistently shows that accuracy drops when you move from large joints like the knee to smaller ones like those in the hand and wrist.
A systematic review comparing ultrasound-guided and landmark-guided injections found that accuracy was greater with ultrasound regardless of the body site, but the advantage was especially pronounced in the small joints of the hand, wrist, and foot. In those locations, ultrasound-guided injections were meaningfully more accurate than landmark-based ones, whereas in larger joints the two approaches performed about equally.4PubMed. Ultrasound versus anatomic guidance for intra-articular and periarticular injection: a systematic review The same review noted that ultrasound-guided injections led to faster symptom relief in the short term, within the first six weeks, though long-term outcomes did not clearly differ between the two approaches.5PubMed. Ultrasound versus anatomic guidance for intra-articular and periarticular injection: a systematic review
A separate review of ultrasound-guided injections in sports medicine confirmed that the hand and wrist joints showed superior benefit from ultrasound guidance compared to landmark technique.6PubMed Central. Existing Evidence on Ultrasound-Guided Injections in Sports Medicine Rheumatologists who use musculoskeletal ultrasound broadly acknowledge that landmark-based injections are not always successful in small or infrequently injected joints, and ultrasound is increasingly recognized as the most practical imaging tool for guiding these procedures in real-time clinical settings.7Best Practice & Research Clinical Rheumatology. Musculoskeletal interventional procedures: With or without imaging guidance?
Whether you should specifically request ultrasound guidance depends partly on availability and partly on the clinical scenario. If a first blind injection failed to help, or if the joint is deformed or very swollen and hard to palpate, ultrasound makes the difference between hitting the joint space and depositing the medication outside it. For a straightforward injection by an experienced injector, the added accuracy may not change the outcome much. But if your doctor offers ultrasound guidance for an MCP injection, there is no downside to accepting it.
What the Injection Feels Like
The honest answer is that it stings, but not as much as most people fear. The MCP joints sit just under the skin on the back of the hand, and the needle used is typically very fine, similar to the gauge used for a tuberculosis skin test. Most of the discomfort happens in the first second as the needle passes through the skin and joint capsule. Once inside the joint space, you may feel a brief sensation of pressure or fullness as the fluid enters.
Some clinics spray the skin with a vapocoolant like ethyl chloride before the injection, hoping the brief numbing effect from the cold will reduce the sting. A clinical study of 151 patients receiving hand injections found no measurable difference in pain scores, post-injection pain, or anxiety between those who received the ethyl chloride spray and those who did not.8PubMed. Use and Effectiveness of Ethyl Chloride for Hand Injections Subgroup analysis showed the spray made no difference regardless of sex, anticipated anxiety, or pain threshold.9PubMed. Use and Effectiveness of Ethyl Chloride for Hand Injections If the spray helps you psychologically, fine, but the data suggests the needle itself is tolerable without it.
After the injection, a brief post-injection flare is common. The joint may feel more sore than it did before for a day or two, especially after the local anesthetic wears off. Ice, rest, and over-the-counter pain relief usually manage this. Most people can resume normal hand use by the next day, though heavy gripping or impact is best avoided for 48 hours or so.
Risks and Complications
Corticosteroid injections into the MCP joints are considered low-risk, but “low-risk” is not “no-risk.” The complications worth knowing about fall into a few categories.
- Post-injection flare: A temporary worsening of pain and swelling in the hours after injection, caused by a crystalline reaction to the steroid suspension. This is self-limited and resolves within a day or two.
- Skin and soft-tissue changes: Repeated injections at the same site can cause thinning of the skin or loss of subcutaneous fat. On the dorsum of the hand, where there is little padding to begin with, this can be cosmetically noticeable and sometimes uncomfortable.
- Infection: Rare with proper sterile technique, but the consequences in a hand joint can be serious. A case report described suppurative extensor tenosynovitis developing after a local steroid injection in the dorsal hand, with progressive bacterial infection ultimately leading to tendon rupture.10PubMed Central. Hazards of steroid injection: Suppurative extensor tendon rupture Cases like this are exceptional, but they underline why any injection site that becomes increasingly red, warm, or swollen in the days after the procedure needs prompt medical attention.
- Tendon weakening: Corticosteroids can degrade collagen, and the extensor tendons of the fingers run directly over the MCP joints. Injections that inadvertently deposit steroid along or into a tendon sheath may increase the risk of tendon weakening over time, particularly with repeated injections.
The risk profile increases with frequency. Most hand specialists advise limiting steroid injections to the same MCP joint to roughly three or four per year. Beyond that threshold, cumulative cartilage exposure to corticosteroid and repeated soft-tissue insult start to outweigh the anti-inflammatory benefit.
Hyaluronic Acid and Other Injectates
Corticosteroids are the default, but they are not the only substance that goes into arthritic hand joints. Hyaluronic acid (HA), a thick gel-like substance that mimics healthy joint fluid, has been studied as an alternative or supplement. Most of the research on HA in the hand focuses on the base of the thumb (the carpometacarpal or trapezio-metacarpal joint) rather than the MCP joints specifically. In that neighboring joint, HA injections have been shown to reduce both resting and activity-related pain while improving hand function, with no serious systemic side effects reported.11PubMed Central. The Effect of Intra-Articular Injections of Hyaluronic Acid for the Treatment of Trapezio-Metacarpal Joint Osteoarthritis
One study of thumb base osteoarthritis compared HA alone to HA combined with ketorolac, an injectable anti-inflammatory. The combination provided faster pain relief at one month, but by three and six months the two groups looked the same, suggesting that the HA itself was doing the heavy lifting for medium-term outcomes while the ketorolac gave an early boost.12PubMed Central. Ultrasound-guided intra-articular injection of hyaluronic acid and ketorolac for osteoarthritis of the carpometacarpal joint of the thumb A retrospective comparative study Whether these results translate directly to MCP joints is unclear, since the thumb base joint has different anatomy and loading patterns. But the principle, that viscosupplementation can provide months of relief in a small hand joint, offers a reasonable basis for trying HA in the MCP joints when steroids are contraindicated or have stopped working.
Platelet-rich plasma (PRP) is another option that has gained popularity across joint injection practice generally, though evidence specific to MCP joints remains thin. PRP involves drawing a sample of your own blood, spinning it to concentrate the platelets and growth factors, and injecting the resulting preparation into the joint. The theoretical appeal is that PRP might promote some degree of tissue repair rather than simply suppressing inflammation. In practice, PRP for small hand joints is still largely experimental, insurance rarely covers it, and the results from larger joints have been mixed enough that it is hard to make strong recommendations for the knuckles.
How the MCP Joint Is Accessed
The standard approach for an MCP joint injection is from the dorsal side of the hand, meaning the back of the knuckle rather than the palm. The extensor tendon runs along the top of the joint, and the needle is typically placed just to one side of that tendon. The patient is usually asked to flex the fingers slightly, which opens up the joint space and makes the target easier to reach.
The dorsal approach is preferred for a simple reason: it avoids the digital nerves and arteries, which run along the sides and palmar surface of the fingers. The skin on the back of the hand is also thinner and more compliant, making needle entry more comfortable than a palmar approach would be. In some clinical situations, particularly when there is significant dorsal swelling or deformity, a lateral approach from the side of the joint may be used instead.
The volume injected is small, usually less than one milliliter total for the steroid-anesthetic mixture. The MCP joint capsule simply cannot accommodate much more than that. If you feel a sudden increase in resistance or the joint becomes tense, the injector should stop, as overfilling creates unnecessary pressure and pain.
Repeat Injections and Diminishing Returns
A single corticosteroid injection into an MCP joint can provide weeks to months of relief, but the duration is highly variable. Some people get three months of meaningful improvement; others notice the pain creeping back within a few weeks. When the first injection works well, it is natural to want another when the effect wears off. The question is how many is too many.
There is no universally agreed-upon hard limit, but the general consensus among hand specialists is that if you need more than three or four injections into the same joint within a year, the injection strategy has reached its ceiling and other interventions should be discussed. Repeated corticosteroid exposure may accelerate cartilage breakdown in joints that are already arthritic, a concern that has been more rigorously studied in larger joints like the knee but is assumed to apply to small joints as well. There is also the cumulative soft-tissue risk described earlier.
When injections stop providing adequate relief, the conversation typically shifts in one of two directions. For inflammatory arthritis like RA, the answer is often a change or escalation of systemic therapy, since the disease is coming from the immune system rather than from mechanical wear. For osteoarthritis, the options narrow toward surgery, most commonly a joint replacement (arthroplasty) at the MCP level or, less often, a fusion. MCP joint replacements using silicone or pyrocarbon implants have been performed for decades and can restore a functional arc of motion, though they are not as durable or well-studied as hip or knee replacements.
MCP Injections in Rheumatoid Versus Osteoarthritis
The reason for the injection affects both expectations and outcomes. In RA, the MCP joints are often involved symmetrically, with multiple knuckles swollen at once. Injecting one or two of the worst-affected joints can provide targeted relief, but the underlying disease process will keep producing inflammation unless systemic therapy is optimized. A steroid injection in RA is a tactical move, not a long-term solution, and patients who find themselves returning for repeated knuckle injections without concurrent disease-modifying drug therapy should ask whether their systemic treatment needs adjustment.
Osteoarthritis at the MCP joints is less common than at the base of the thumb or the finger tip joints but does occur, especially after old injuries or in people with occupations involving repetitive hand stress. In OA, the joint damage is primarily mechanical, and a steroid injection calms the inflammation that flares around damaged cartilage but does nothing to rebuild what has been lost. The relief tends to be shorter-lived with progressive OA, and each successive injection may seem to work less well as the structural damage advances.
Gout at the MCP joints deserves its own mention because the injection serves a dual purpose: it treats the acute attack, and the fluid aspirated from the joint before injecting can be examined under a microscope for urate crystals, confirming the diagnosis. If your doctor suspects gout in a knuckle, they may attempt to aspirate even a tiny amount of fluid before injecting the steroid. The crystal analysis can guide long-term treatment decisions that go well beyond the injection itself.
When to Seek Evaluation Instead of Another Injection
Not every painful MCP joint needs an injection, and not every injection that did not work means you need a different injection. There are scenarios where the right move is further evaluation rather than another needle.
If an injection provided no relief at all, even in the first day when the anesthetic should have helped, the pain may not be coming from inside the joint. Extensor tendon problems, ganglion cysts, and nerve entrapments can all mimic MCP joint pain and will not respond to an intra-articular steroid. A missed diagnosis is one of the most common reasons hand injections “fail.” Ultrasound or MRI can help sort out whether the joint itself is the culprit.
Rapidly worsening symptoms after an injection, particularly increasing redness, warmth, and swelling developing over days rather than hours, raise concern for infection and warrant urgent evaluation. A post-injection flare improves within 48 hours; an infection gets steadily worse. The distinction matters because a septic joint in the hand can cause permanent damage if not treated quickly with antibiotics and sometimes surgical drainage.
Finally, if you have been receiving injections into multiple hand joints several times a year and have not been evaluated by a rheumatologist, that referral is overdue. A pattern of polyarticular hand inflammation usually points to a systemic condition that needs systemic treatment, and continuing to chase individual joints with a needle is treating the smoke rather than the fire.